{
  "source": "PA-Notification-Nityr.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1229-8\nProgram Prior Authorization/Notification\nMedication Nityr® (nitisinone)\nP&T Approval Date 9/2017, 9/2018, 9/2019, 9/2020, 9/2021, 9/2022, 9/2023, 9/2024\nEffective Date 12/1/2024\n1. Background:\nNityr® (nitisinone) is a hydroxyphenyl-pyruvate dioxygenase inhibitor indicated for the treatment\nof adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with\ndietary restriction of tyrosine and phenylalanine.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Nityr will be approved based on the following criteria:\na. Diagnosis of hereditary tyrosinemia type 1\n-AND-\nb. Nityr is being used as an adjunct to diet modification\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Nityr will be approved based on the following criterion:\na. Patient shows evidence of positive clinical response (e.g., decrease in\nurinary/plasma succinylacetone and alpha-1-microglobulin levels) while on Nityr\ntherapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n© 2024 UnitedHealthcare Services, Inc.\n1\n• Supply limits may be in place.\n4. References:\n1. Nityr [package insert]. Cambridge, United Kingdom. Cycle Pharmaceuticals Ltd.; January\n2024.\nProgram Prior Authorization/Notification – Nityr (nitisinone) tablets\nChange Control\n9/2017 New program\n9/2018 Annual review with no changes to coverage criteria.\n9/2019 Annual review with no changes to coverage criteria. Upd",
    "on/Notification – Nityr (nitisinone) tablets\nChange Control\n9/2017 New program\n9/2018 Annual review with no changes to coverage criteria.\n9/2019 Annual review with no changes to coverage criteria. Updated reference.\n9/2020 Annual review with no changes to coverage criteria. Updated reference.\n9/2021 Annual review. Changed reauthorization approval duration to 12\nmonths. Updated reference.\n9/2022 Annual review with no changes to coverage criteria. Added state\nmandate disclaimer.\n9/2023 Annual review with no changes to coverage criteria. Updated\nbackground.\n9/2024 Annual review with no changes. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}